Residency · Residency · Neurology

Narcolepsy and Central Disorders of Hypersomnolence

Introduction

Central disorders of hypersomnolence are characterized by excessive daytime sleepiness (EDS) that is not attributable to insufficient sleep, circadian rhythm disorders, or sleep-disordered breathing. Narcolepsy is the prototypical disorder in this category, and advances in understanding hypocretin (orexin) neurobiology have transformed its diagnosis and treatment.

Narcolepsy Type 1 (Narcolepsy with Cataplexy)

Pathophysiology

Narcolepsy type 1 results from the selective destruction of hypocretin (orexin)-producing neurons in the lateral hypothalamus. The etiology is likely autoimmune, supported by the extraordinarily strong association with HLA-DQB1*06:02, which is present in more than 98% of NT1 patients. T-cell-mediated destruction eliminates approximately 70,000 to 90,000 hypocretin neurons, resulting in very low or undetectable CSF hypocretin-1 (orexin-A) levels, defined as less than 110 pg/mL. Environmental triggers that have been implicated include H1N1 influenza infection and the AS03-adjuvanted Pandemrix vaccine.

Clinical Features

Excessive daytime sleepiness manifests as irresistible sleep attacks, often with refreshing naps. Cataplexy, the pathognomonic feature of NT1, is a sudden bilateral loss of muscle tone triggered by strong emotions such as laughter, surprise, or anger. Episodes range from subtle jaw sagging or head drop to complete postural collapse, with consciousness preserved throughout and duration lasting seconds to minutes. Sleep paralysis presents as an inability to move at sleep-wake transitions. Hypnagogic and hypnopompic hallucinations are vivid, often frightening visual or multimodal experiences occurring at sleep onset or upon awakening. Disrupted nocturnal sleep with frequent awakenings and vivid dreams is also characteristic. Symptom onset typically occurs in adolescence or young adulthood with a bimodal peak at ages 15 and 35.

Diagnosis

The Multiple Sleep Latency Test (MSLT) demonstrates a mean sleep latency of 8 minutes or less with 2 or more sleep-onset REM periods (SOREMPs); a SOREMP on the preceding night PSG counts as one of the two required. CSF hypocretin-1 levels less than or equal to 110 pg/mL (or less than one-third of normal) are diagnostic and can replace the MSLT. Polysomnography the night before the MSLT is required to exclude other sleep disorders and confirm adequate sleep time.

Narcolepsy Type 2 (Narcolepsy without Cataplexy)

Narcolepsy type 2 presents with EDS meeting MSLT criteria (mean sleep latency 8 minutes or less with 2 or more SOREMPs) but without cataplexy. CSF hypocretin-1 levels are typically normal or intermediate. This may represent a less severe or early form of the disease, and approximately 10% of patients develop cataplexy over time. NT2 is a diagnosis of exclusion requiring elimination of insufficient sleep syndrome, sleep apnea, and circadian disorders.

Idiopathic Hypersomnia

Idiopathic hypersomnia presents with chronic excessive sleepiness, prolonged nocturnal sleep often exceeding 10 hours, and severe sleep inertia (sleep drunkenness) upon awakening that distinguishes it from narcolepsy. The MSLT shows a mean sleep latency of 8 minutes or less but fewer than 2 SOREMPs, or alternatively, total 24-hour sleep time exceeds 11 hours on ad libitum PSG or actigraphy. CSF hypocretin levels are normal. There is no definitive biomarker, and diagnosis remains clinical with polysomnographic support.

Kleine-Levin Syndrome

Kleine-Levin syndrome is a rare disorder predominantly affecting adolescent males, characterized by recurrent episodes of hypersomnia lasting days to weeks with intervening periods of normal function. Associated features during episodes include cognitive dysfunction, hyperphagia, hypersexuality, and derealization. Episodes decrease in frequency and severity over years. The etiology remains unknown, though possible autoimmune or inflammatory mechanisms have been proposed. No consistently effective treatment exists, though lithium may reduce episode frequency.

Treatment of Narcolepsy

Wake-Promoting Agents for EDS

Modafinil and armodafinil are first-line agents with a mechanism not fully understood but generally well tolerated. Solriamfetol is a dual-acting dopamine and norepinephrine reuptake inhibitor effective for EDS. Pitolisant is a histamine H3 receptor inverse agonist that promotes wakefulness through the histaminergic pathway. Methylphenidate and amphetamines are traditional stimulants that remain effective but carry higher abuse potential and cardiovascular side effects.

Treatment of Cataplexy

Sodium oxybate (gamma-hydroxybutyrate) is highly effective for both cataplexy and EDS while also improving nocturnal sleep fragmentation; it is taken in two nightly doses. Low-sodium oxybate (calcium, magnesium, potassium, sodium oxybates) offers equivalent efficacy with lower sodium content. Antidepressants including venlafaxine, fluoxetine, and clomipramine suppress REM sleep and reduce cataplexy. Abrupt withdrawal of anticataplectic medications must be avoided due to the risk of status cataplecticus.

Emerging Therapies

Orexin receptor agonists such as danavorexton and TAK-994 aim to replace the missing neuropeptide signal and are in clinical trials. Immunotherapy in early disease has shown promise in case reports, with IVIg potentially beneficial when given near symptom onset.

Non-Pharmacological Measures

Scheduled brief naps of 15 to 20 minutes taken once or twice daily can reduce sleepiness. Maintaining a regular sleep-wake schedule with adequate nocturnal sleep is important. Avoidance of known cataplexy triggers when possible, patient education and support, and driving safety counseling round out the non-pharmacological approach.

Clinical Pearls

Cataplexy triggered by positive emotions, especially laughter, is virtually pathognomonic for narcolepsy type 1 and distinguishes it from syncope, seizures, and psychogenic episodes. CSF hypocretin-1 measurement can definitively diagnose NT1 without requiring an MSLT, which is particularly useful when stimulant medications cannot be withdrawn. MSLT results are unreliable unless preceded by at least 2 weeks of adequate sleep and discontinuation of REM-suppressing medications such as antidepressants. Idiopathic hypersomnia is distinguished from narcolepsy by profound sleep inertia, prolonged unrefreshing sleep, and absence of SOREMPs on MSLT. Sodium oxybate is the only medication with robust evidence for treating both cataplexy and EDS in narcolepsy.

References

1. Bassetti CLA, Adamantidis A, Burdakov D, et al. Narcolepsy: clinical spectrum, aetiopathophysiology, diagnosis, and treatment. Nat Rev Neurol. 2019;15(9):519-539.
2. Mahoney CE, Cogswell A, Koralnik IJ, Bhatt MH. The neurobiological basis of narcolepsy. Nat Rev Neurosci. 2019;20(2):83-93.
3. Thorpy MJ, Krieger AC. Delayed diagnosis of narcolepsy: characterization and impact. Sleep Med. 2014;15(5):502-507.
4. Arnulf I. Idiopathic hypersomnia. Sleep Med Clin. 2023;18(3):303-315.

Read this lecture as Markdown